Digestive system neuroendocrine neoplasm
MONDO:0024503A neoplasm with neuroendocrine differentiation arising from the digestive system. It includes neuroendocrine tumors (well-differentiated endocrine tumors or carcinoid tumors and well differentiated endocrine carcinomas) and neuroendocrine carcinomas (poorly differentiated neuroendocrine carcinomas, small cell carcinomas, and large cell neuroendocrine carcinomas).
Also known as: alimentary part of gastrointestinal system NET, alimentary part of gastrointestinal system neuroendocrine neoplasm, alimentary part of gastrointestinal system neuroendocrine tumor, alimentary part of gastrointestinal system neuroendocrine tumor, well differentiated, low or intermediate grade, alimentary part of gastrointestinal system neuroendocrine tumour, carcinoid tumor of digestive system, carcinoid tumour of digestive system, digestive system NET
1626 clinical trials for this condition and its sub-types, 52 tagged with Digestive system neuroendocrine neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Digestive system neuroendocrine neoplasm
-
Digestive system neuroendocrine tumor, grade 1/2 66 trials · 145 incl. sub-types
10 sub-types
- Pancreatic neuroendocrine tumor 60 trials · 77 incl. sub-types Sub-types →
- Small intestine neuroendocrine tumor, well differentiated, low or intermediate grade 4 trials · 9 incl. sub-types Sub-types →
- Intestinal neuroendocrine tumor G1 5 trials · 8 incl. sub-types Sub-types →
- Neuroendocrine tumor of the colon, well differentiated, low or intermediate grade tumor 0 trials · 5 incl. sub-types Sub-types →
- Gastric neuroendocrine tumor, well differentiated, low or intermediate grade 2 trials · 4 incl. sub-types Sub-types →
- Rectal neuroendocrine tumor 3 trials · 4 incl. sub-types Sub-types →
- Esophageal neuroendocrine tumor 1 trial · 3 incl. sub-types Sub-types →
- Gastrin-producing neuroendocrine tumor 3 trials Sub-types →
- L-cell glucagon-like peptide-producing neuroendocrine tumor 0 trials Sub-types →
- Gallbladder neuroendocrine tumor, grade 1/2 0 trials
-
Pancreatic neuroendocrine neoplasm 9 trials · 85 incl. sub-types
2 sub-types
- Pancreatic neuroendocrine tumor 60 trials · 77 incl. sub-types Sub-types →
- Pancreatic endocrine carcinoma 12 trials Sub-types →
-
Intestinal neuroendocrine neoplasm 7 trials · 21 incl. sub-types
4 sub-types
- Small intestine neuroendocrine neoplasm 0 trials · 9 incl. sub-types Sub-types →
- Intestinal neuroendocrine tumor G1 5 trials · 8 incl. sub-types Sub-types →
- Rectum neuroendocrine neoplasm 3 trials · 6 incl. sub-types Sub-types →
- Colon neuroendocrine neoplasm 0 trials · 5 incl. sub-types Sub-types →
-
Gastric neuroendocrine neoplasm 3 trials · 6 incl. sub-types
2 sub-types
- Gastric neuroendocrine tumor, well differentiated, low or intermediate grade 2 trials · 4 incl. sub-types Sub-types →
- Gastric small cell neuroendocrine carcinoma 0 trials
-
Liver neuroendocrine carcinoma 3 trials
2 sub-types
-
Gallbladder neuroendocrine neoplasm 0 trials
2 sub-types
-
Salivary gland small cell carcinoma 0 trials
Most studied deeper sub-types
-
New hope for rare, aggressive cancers: immune therapy targets hard-to-treat tumors
Disease control Stopped earlyThis study tests a drug called tarlatamab, which helps the immune system find and attack cancer cells. It is for people with advanced neuroendocrine carcinomas of the digestive system or unknown origin, a rare and aggressive cancer with limited treatment options. About 87 partici…
Phase 2 • Sponsor: Grupo Espanol de Tumores Neuroendocrinos • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Promising cancer drug trial halted after just one patient
Disease control Stopped earlyThis study aimed to see if giving Lutathera (a radioactive drug) after surgery to remove liver metastases from neuroendocrine tumors could help keep the cancer from coming back. It planned to compare Lutathera plus best supportive care against best supportive care alone in about …
Phase 2 • Sponsor: Imperial College London • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New 12-Week hormone therapy studied for rare tumors
Disease control Stopped earlyThis early-phase study tested a new formulation of octreotide (Debio 4126) that lasts 12 weeks, aiming to control hormone levels in people with acromegaly or certain neuroendocrine tumors. Only 19 participants were enrolled before the trial was terminated. The main goal was to me…
Phase 1 • Sponsor: Debiopharm International SA • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC